The Moderna Nasdaq-100 entry takes effect before the U.S. market opens on October 9, adding the biotechnology company to one of the most widely tracked growth indexes. Nasdaq announced the change on October 1 and said Moderna will replace Warner Bros. Discovery.

The change gives Moderna exposure to index products that track the Nasdaq-100, although inclusion does not guarantee a positive share-price response. Nasdaq said more than 200 investment products with over $800 billion in global assets follow the benchmark.

Key Insights

  • The Moderna Nasdaq-100 entry becomes effective before trading begins on October 9, replacing Warner Bros. Discovery.
  • Nasdaq said more than 200 investment products with over $800 billion in assets track the index globally.
  • Investors will next assess how index-related demand interacts with Moderna’s pipeline progress, costs, revenue outlook, and upcoming earnings.

Moderna Nasdaq-100 Entry Takes Effect Today

Nasdaq said Moderna would become a component of the Nasdaq-100 before the October 9 market open. The company trades under the MRNA ticker and has been listed on the Nasdaq Global Select Market since December 2018.

The benchmark includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market by market capitalization. Its industry coverage includes biotechnology alongside technology, telecommunications, retail, and other large non-financial businesses.

Moderna replaces Warner Bros. Discovery in the index rather than joining through the annual December reconstitution. That makes the change a targeted constituent replacement tied to the outgoing company’s removal.

Index Inclusion Can Expand Institutional Exposure

Funds and structured products designed to replicate the Nasdaq-100 must generally align their holdings with the index’s updated composition. The resulting transactions can increase trading activity around the effective date, but the size and direction of any market reaction depend on liquidity, portfolio implementation, and broader conditions.

Nasdaq reported that more than 200 investment products with over $800 billion in assets under management track the index globally. That figure describes the full product ecosystem and should not be treated as money that will move directly into Moderna shares.

The inclusion also broadens the healthcare representation inside a benchmark often associated with large technology companies. Moderna’s index role will now place the company alongside established biotechnology and healthcare constituents while preserving the Nasdaq-100’s non-financial focus.

Pipeline Execution Remains the Central Stock Test

The Moderna Nasdaq-100 entry changes the company’s benchmark status, not its underlying operating performance. Investors still need to assess product demand, research spending, regulatory outcomes, cash use, and the commercial prospects of Moderna’s mRNA pipeline.

At its last quarterly update, Moderna reported second-quarter revenue of $0.1 billion and a GAAP net loss of $0.8 billion. The company also maintained its plan for up to 10% revenue growth in 2026 and projected a year-end cash balance of $4.7 billion to $5.2 billion.

That earnings profile creates a different investment question from the clinical milestone covered in Fusion Market News’ report on Pulse Biosciences’ heart trial. It also differs from the balance-sheet pressures in Applied Digital’s quarterly results and the monetary-policy outlook in the latest Federal Reserve minutes.

The next observable catalyst will be the first trading session with Moderna inside the index, followed by the company’s next earnings and pipeline updates. Those events will show whether benchmark-related demand is supported by improving operating fundamentals.

Elsy Kanana is a financial and cryptocurrency journalist at FusionMarketNews, covering digital assets, blockchain technology, financial markets, and emerging fintech trends. Her reporting focuses on market movements, regulatory developments, and on-chain analytics, delivering clear, data-driven insights to readers worldwide.